Main Article Content

Wajiha Imam
Hafiza Qurat Ul Ain
Yusra Aimen
Umer Javed


Adjuvant aspirin, Hepatitis B, Hepatocellular carcinoma, Portal vein tumor thrombus


Objectives: To compare the recurrence free and overall survival with either post-operative adjuvant use of aspirin or surgery alone in patients having hepatitis B related hepatocellular carcinoma and portal vein tumor thrombus.  

Study Design: Randomized controlled trial.

Place and duration of study: This study was conducted at CMH Hospital, Multan from the 1st of July 2022 to the 31st of December 2023.

Methods: A total of 120 patients above the age of 20 years diagnosed with hepatitis B related resectable HCC and associated PVTT, fulfilling the criteria for surgical procedure and planned for surgical resection were included and randomized into 2 equal groups of 60 patients each.

In Group A patients were recommended adjuvant aspirin at a dose of 75 mg daily while in Group B patients were not given this adjuvant therapy.  Primary outcomes of the study were set as recurrence free survival and overall survival at the end of 1 year study period while the secondary outcomes were time duration until any recurrence of the primary tumor was reported and time duration until the recurrence of the tumor in the portal vein was reported. 


Results: The Mean±SD of age in this study was 55±6.76 years. The results of the primary outcomes of the study show significantly better recurrence free survival (70% Vs 50%, p=0.025) and overall survival (83.33% Vs66.66%, p=0.035) in Group A compared to Group B. Similarly, the results of secondary outcomes of the study show significantly longer duration for diagnosis of primary tumor (10.33±2.6 Vs 8.33±3.55 months, p=0.015) and diagnosis of portal vein tumor (10.9±2.02 Vs9.6±2.27 months, p=0.022) in Group-A compared to Group-B.


Postoperative adjuvant aspirin significantly increases the recurrence free and overall survival of patients having hepatitis B related hepatocellular carcinoma and portal vein tumor thrombus. 

Abstract 155 | Pdf Downloads 25


1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492.
2. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288.
3. Singal AG, Lampertico P, Nahon P. Epidemiology and surveil-lance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250—61.
4. European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019.
5. Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Vil-lanueva A. Tumour evolution in hepatocellular carcinoma. NatRev Gastroenterol Hepatol. 2020;17(3):139—52.
6. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.
7. Chen M, Hu J, Cao J, Cai X. Comprehensive considerationbefore the decision-making of the systemic treatment in patients with advanced hepatocellular carcinoma. Liver Cancer. 2020;9(2):221—2.
8. Vogel A, Saborowski A. Current strategies for the treatment ofintermediate and advanced hepatocellular carcinoma. CancerTreat Rev 2020;82:101946.
9. Palacios-Acedo AL, Mege D, Crescence L, Dignat-George F,Dubois C, Panicot-Dubois L. Platelets, thrombo-inflammation,and cancer: collaborating with the enemy. Front Immunol.2019;10:1805.
10. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2015;16(13):1344e54.
11. Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K et al. Add-Aspirin Trial Management Group. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterol Hepatol. 2019 Nov;4(11):854-862. doi: 10.1016/S2468-1253(19)30289-4.
12. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, et al. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018 Dec 1;4(12):1683-1690. doi: 10.1001/jamaoncol.2018.4154. Erratum in: JAMA Oncol. 2019 Apr 1;5(4):579.
13. Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ, Su CW, Huo TI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC. Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Ann Surg Oncol. 2016 Dec;23(Suppl 5):874-883. doi: 10.1245/s10434-016-5520-9.
14. Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer. 2020 Jan;9(1):28-40. doi: 10.1159/000503685.
15. Wang S, Zuo L, Lin Z, Yang Z, Chen R, Xu Y. The relationship between aspirin consumption and hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Med Res. 2023 Jul 8;28(1):226. doi: 10.1186/s40001-023-01204-5.
16. Boas FE, Brown KT, Ziv E, Yarmohammadi H, Sofocleous CT, Erinjeri JP, Harding JJ, Solomon SB. Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma. AJR Am J Roentgenol. 2019 Sep;213(3):1-7.
doi: 10.2214/AJR.18.20846.
17. Young SH, Chau GY, Lee IC, Yeh YC, Chao Y, Huo TI et al. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. J Formos Med Assoc. 2020 Jan;119(1 Pt 2):218-229. doi: 10.1016/j.jfma.2019.04.018.
18. Li X, Yu Y, Liu L. Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101545. doi: 10.1016/j.clinre.2020.09.006.
19. Lu CD, Jiang YB, Feng JK, Wang L, Wei XB, Zhou B et al. Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial. Heliyon. 2023 Sep 9;9(9):e20015.
doi: 10.1016/j.heliyon.2023.e20015.